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Side effects of retinoid therapy on the quality of vision
Retinoids are compounds chemically related to vitamin A, 
which are frequently used in dermatological practice (1). 
They are characterized by numerous mechanisms of ac-
tion leading to normalization of keratinocyte proliferation 
and maturation. They have anti-seborrhoeic, immuno-
modulatory and anti-inflammatory effects (1, 2). A number 
of side effects to retinoid treatment have been recorded; 
one group of such side effects relates to eyes and vision. 
Dry eye syndrome and blepharoconjunctivitis are the most 
common side effects, appearing in 20–50 % of patients 
treated with retinoids. They often contribute to the occur-
rence of other side-effects such as eye discomfort and con-
tact lens intolerance. Due to the widespread use in clinical 
practice, the adverse effects, including ocular side effects, 
should be studied. To confirm the variety of adverse effects 
of retinoids, several case reports of rare side-effects are 
presented.
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Retinoids are compounds chemically related to vitamin A (1, 2); they can be presented 
through 3 generations (2):
(i)  first generation, which includes alitretinoin (9-cis-retinoic acid), retinaldehyde, 
retinol, isotretinoin (13-cis-retinoic acid), tretinoin (trans-retinoic acid);
(ii)  second generation, whose representatives are acitretin and etretinate;
(iii)  third generation, which includes adapalene, arotinoid, arotinoid ethyl, methyl 
sulfone arotynoid, bexarotene, tazarotene.
Mechanisms of action of vitamin A derivatives inter alia rely on:
(i)  reducing the expression of matrix metalloproteinases (MMP) such as collage-
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(ii)  blocking the activity of 3α-hydroxysteroid dehydrogenase of retinol (2);
(iii)  inhibiting the transcription factor-activator protein 1 (AP-1) (2);
(iv)  blocking the cell-division cycle (2);
(v)  inducing apoptosis of sebocytes as well as their stem cells and precursor cells of 
the sebaceous glands, which result in a long-lasting effect of retinoids (4).
Retinoids affect human cells at the stages of embryogenesis, reproduction, regulation 
of inflammatory process, cell growth and differentiation (5). As ligands, they modify the 
DNA transcription through interaction with the retinoic acid receptors (RAR) and reti-
noid-X-receptors (RXR) – nuclear receptors that serve as transcription factors (1, 5). After 
ligand binding, dimerisation of receptors and interaction with DNA, co-activators are re-
cruited and RNA elongation is performed (5). By inhibiting growth-stimulating signals 
and activating downstream signaling they regulate apoptosis and cell differentiation in 
pre-cancerous and cancerous lesions (5). The anti-inflammatory and anti-bacterial action 
can be seen in the influence on immune response to Propionibacterium acnes through reduc-
ing the expression of the toll-like-receptor 2 (TLR2) on immune system cells responsible 
for pro-inflammatory cytokines production (4, 5). All these mechanisms lead to the nor-
malization of keratinocyte proliferation and maturation, immunomodulatory and anti-
inflammatory effects of these medicaments (5).
The use of systemic retinoids is widespread. Acitretin is used orally in patients with 
severe and erythrodermic psoriasis vulgaris resistant to other therapies, generalized and 
localized pustular psoriasis, severe congenital ichthyosis, Darier’s disease, pityriasis rubra 
piliaris, recalcitrant lichen planus and palmoplantar keratoderma (1, 7, 8). Alitretinoin is 
effective in severe chronic hand eczema (5, 8). Tretinoin is used in acute promyelocytic 
leukemia treatment (1). Bexarotene is approved for the cutaneous T-cell lymphoma therapy 
and it demonstrates promising effects in some cancers like non-small cell lung cancer. It is 
Table I. Guidelines of care for the management of acne vulgaris (10)
Acne Mild Moderate Severe
First 
choice






oral antibiotic + topical retinoid + BP 
or
oral antibiotic + topical retinoid + BP 
+ topical antibiotic


























BP – benzoyl peroxide 
* Topical combination therapy: BP + antibiotic or BP + retinoid or BP + retinoid + antibiotic
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also used in mycosis fungoides and Sézary syndrome in combination with other forms of 
therapy (9). The effectiveness of isotretinoin in the treatment of acne was first observed in 
1970. In 1982, the Food and Drug Administration (FDA) approved its oral form as a drug 
used for acute forms of nodular acne (6). Actually, isotretinoin is mainly administrated to 
treat severe acne vulgaris according to recommendations for the use of retinoids in acne, 
which are contained in ref. 10 and presented in Table I. Less frequent indications include 
hidradenitis suppurativa, selected cases of acne rosacea and some other hyperkeratotic 
dermatological conditions (2).
Many conditions may be treated with the topical form of vitamin A derivatives. 
Topical tretinoin  is effective in  acne therapy but is also used in other skin disorders, 
including  premature skin aging induced by ultraviolet light, actinic keratosis and other 
less described conditions, e.g., lesions of oral mucosa, hypertrophic scarring, pigmenta-
tion disorders (11). Topical alitretinoin is administrated in Kaposi’s sarcoma patients with 
human immunodeficiency virus (HIV) infection. Some other retinoids, such as adapalene, 
may be used in acne vulgaris and tazarotene in combination with topical corticosteroids 
in psoriasis (1). Topically used retinoids differ in the potential to induce local side-effect, 
irritation, erythema and in particular exfoliation of skin (5). The wide range of substances 
allow the physician to make selection for an individual patient in search of the best toler-
ance. In our opinion, it is valid for clinicians to select the most suitable medicament but it 
is also important to pay attention to systemic uptake of retinoids applied onto skin, espe-
cially on extensive areas of the body. Shiva et al. (12) pointed out that external application 
of isotretinoin causes its penetration into the circulatory system. We expect that it may 
demonstrate systemic activity, as well as cause systemic side-effects. The same authors 
showed that the tolerance elevates when specific new solid-lipid nanoparticles of isotreti-
noin are used. Moreover, such form of isotretinoin can prevent its systematic uptake. 
The most commonly used oral retinoid in dermatological practice is isotretinoin, it 
will therefore be the basis of discussion regarding the adverse effects of vitamin A deriva-
tives, paying particular attention to the ocular symptoms. 
ADVERSE OCULAR EFFECTS
Isotretinoin is an effective and generally well tolerated drug (6, 13). Many of the ad-
verse effects can be predicted before they occur (13). The most common side-effects rarely 
reach the severity that could require discontinuation of treatment and they disappear 
a short time after the cessation of therapy (13).
The adverse effects of isotretinoin therapy, in dependence on the frequency of occur-
rence, are shown in Table II (2).
Analyzing 1,741 reports of possible ocular adverse effects induced by isotretinoin 
Fraunfelder et al. (13) divided them into the following categories according to World Health 
Organization (WHO) in the Causality Assessment Guide of Suspected Adverse Reactions: 
“certain,” “probable/likely,” “possible,” “unlikely,” “conditional/unclassified,” and unas-
sessible/unclassifiable”. Section “certain” includes: abnor mal meibomian gland secretion, 
blepha roconjunctivitis, corneal opacities, decreased dark adaptation, photophobia, de-
creased tolerance to contact lenses, decreased vi sion, increased tear osmolality, myopia, 
ocular dis comfort, ocular sicca (dry eye syndrome), pseudotumor cerebri (when adminis-
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trated simultaneously with oral tetracycline), keratitis and teratogenic ocular abnormali-
ties. Most of these symptoms are reversible and pass after discontinuation of retinoid treat-
ment (13). The list of side effects is long but, in our experience, the most common ocular 
adverse effects are the dry eye syndrome and blepharoconjunctivitis. They occur in 20–50 % 
of patients taking the drug, usually 3–5 weeks after initiation of the therapy (2, 14).
Dry eye is caused by atrophic changes in meibomian glands (15, 16) as well as modi-
fication of the tear film composition (15). Meibomian glands are tarsal sebaceous glands 
responsible for the production of meibum, an oily substance, the most superficial layer of 
the tear film that protects it from evaporation and dysfunctions (15). Lambert and Smith 
(16) studied the impact of retinoids on the morphological cell structure. They found that 
isotretinoin inhibits the differentiation of meibomian acinar cells and stimulates prolife-
ration of the epithelium lining the ducts and acini causing their thickening. Mathers et al.´ s 
examination (17) of the meibomian gland morphology and tear osmolality showed that 
during retinoid treatment the meibomian glands become significantly less dense, atrophic 
and the osmolality of the tear film increases. Nevertheless, these changes had no impact 
on the Schirmer test results used to assess the secretion of tears.
Meibomian gland excretion prevents excessive evaporation of the aqueous layer of the 
tear film and secures film osmolality and stability. Thus, dysregulation causes secondary 
dryness and irritation of the most external structures of the eye: conjunctiva and cornea 
(18). In our opinion, this might be assumed as an indirect effect of retinoid acid whereas 
direct action should also be taken into consideration. It is caused by the presence of the 
drug and its metabolites in the tear film (14), which may directly provoke its instability, 
hence dryness and irritation. We emphasize that both of these mechanisms are predis-
Table II. Adverse effects of isotretinoin therapy and frequency of occurrence (ref. 2)
Frequency of 
occurrence




Cheilitis, dryness, peeling, itching, redness of the skin; features resembling hand ecze-
ma; increase of transaminases; increase of triglycerides; muscle and joint pain; decreased 
exercise tolerance; decreased high-density lipoprotein; dry eye; irritation of the eye; 
blepharitis; conjunctivitis; night vision disturbances; anemia; accelerated erythrocyte 
sedimentation rate; thrombocytopenia; thrombocytosis
Common  
(>1/100)
Neutropenia, headache, epistaxis, dryness of nose mucus membrane, increase of the cho-
lesterol and glucose concentration, hematuria, proteinuria
Rare 
(>1/10.000)




Bacterial infections of the skin and mucous membranes, lymphadenopathy, diabetes, 
hyperuricemia, abnormal behavior, suicidal ideation, pseudotumor cerebri (when ad-
ministrated simultaneously with oral tetracycline), drowsiness, seizures, blurred vision, 
cataract, color vision disorder, intolerance of contact lenses, keratitis, photophobia, im-
paired hearing, allergic vasculitis, Wegener’s granulomatosis, pancreatitis, hepatitis, 
fulminant acne, exacerbation of acne, hirsutism, nail dystrophy, paronychia, hyperpig-
mentations, photosensitivity, myositis and arthritis, tendonitis, increase of creatine phos-
phokinase
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posed to ocular adverse effects such as conjunctivitis, blepharitis, intolerance of contact 
lenses and photophobia.
Neudorfer et al. (18) conducted a retrospective cohort study involving 14,682 adolescents 
and young adults with a recommended daily dose of isotretinoin of 0.5–1.0 mg kg–1, to a 
cumulative dose of 120 to 150 mg kg–1. Adverse ocular effects were measured within 1 year 
after the first dispensed isotretinoin prescription. In group I, with new users of isotretinoin 
for acne,  13.8 % of the patients reported adverse ocular effects; in group II, with acne but 
without isotretinoin treatment  9.6 %, and in group III, which was a control group,  7.1 %. 
During a one-year follow-up period, the first group showed a significantly increased risk of 
ocular symptoms. This significantly increased risk was not found in the second group. The 
dry eye risk was reported in 0.7, 0.2  and 0.1 % of patients in the respective groups.
In the Bergler-Czop study (2), out of 155 patients treated with oral isotretinoin because 
of different forms of acne (examined before qualifying for treatment, at the beginning of 
treatment, and during the 3rd and the 6th months of treatment), dry eye was observed in 50 
% of patients during later treatment periods. 
Karalezli et al. (14) conducted a prospective clinical study examining 50 patients treat-
ed with isotretinoin at a daily dose of 0.8 mg kg–1. The patients underwent a full ophthal-
mologic examination before treatment, during treatment (on the 30th and 120th day), at the 
end of treatment, and 30 days after the treatment. The average results of the Schirmer test 
performed at each examination time point did not differ significantly, while the mean 
anesthetized Schirmer test and tear breakup time (TBUT, which reflects the stability of the 
tear film) results decreased. The scores of ocular surface disease index (OSDI, which as-
sesses the symptoms associated with the dryness of eyes and their effects on vision) were 
elevated.
Cumurcu et al. (19) compared how the high-dose and low-dose isotretinoin treatments 
aff ect the vision. A group of 26 patients were treated with the high dose (> 0.5 mg kg–1 
daily) of the drug and 25 patients with the low dose (< 0.5 mg kg–1 daily). Ophthalmological 
examination took place before the treatment, on the 45th and 90th day of treatment and one 
month after treatment. The authors did not observe any statistically significant difference 
between these two groups in the results of the Schirmer test with anesthesia. The duration 
of TBUT on days 45 and 90 was significantly shorter in the group taking the higher dose 
of retinoid, with no difference in the results before and after the treatment.
Another frequently observed adverse effect of therapy is blepharoconjunctivitis. 
Karalezli et al. (14) observed blepharitis in 36 % of patients 1 month after the cessation of 
treatment. It was accompanied by dysfunction of meibomian glands, hyperemia and vas-
cularization of the lid margin. In the Fraunfelder et al. (13), 15 % of patients had blepharo-
conjunctivitis during isotretinoin treatment.
Neudorfer et al. (18), in the previously mentioned study, recorded the following inci-
dence of conjunctivitis after a 1-year observation period: 4.0 % in group I (new users of 
isotretinoin for acne), 2.4 % in group II (patients with acne but without isotretinoin treat-
ment), and 1.9 % in the group III (control group), while blepharitis was observed in par-
ticular groups in 1.0, 0.2  and 0.2 %, respectively.
Night and color vision disturbances are among the most serious side-effects of reti-
noids (20). Night vision abnormalities are most likely associated with the fact that isotret-
inoin inhibits retinol dehydrogenase, which leads to the reduction of 11-cis-retinal and 
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thus causes functional impairment of rod photoreceptors (2, 20). Toxic doses of isotretinoin 
do not cause histological loss of rod cells, but even a single dose of the drug causes slower 
recovery of rod signaling and rhodopsin regeneration for several days (21). Rare cases have 
been reported of irreversible night vision disturbance, which seems to be an idiosyncratic 
reaction not related to the dose (20).
Mollan et al. (22) examined 47 patients treated with oral isotretinoin in the past. They 
underwent standard electroretinograms (ERG), which measure the electrical responses to 
standardized stimuli of various cell types in retina, and the Goldmann-Weekers dark adap-
tation test (DA), which represents the ability of eye to adapt to darkness. Thirteen patients 
had ERG changes showing night vision disturbances, and 2 of them had also abnormal DA.
Fraunfelder and colleagues (13) conducted a study of 1,741 patients and noted de-
creased dark adaptation in 8 % of them.
SOME CLINICAL CASES
Corneal steepening (23). – A 39-year-old female patient, taking isotretinoin (20 mg kg–1 
daily) for seven and a half weeks, experienced blurred vision, transient loss of some parts 
of her visual field, dry eyes, peeling and erythema of the face and lips. Examination re-
vealed a number of abnormalities, including conjunctival hyperemia, punctate corneal 
staining and meibomian gland dysfunction. Corneal topography showed changes in the 
shape of cornea – corneal steepening more intensified in peripheral parts. Refraction of 
eyes showed no significant changes compared to previous results of the patient. After ces-
sation of isotretinoin treatment, the reported symptoms disappeared and corneas returned 
to normal structure after 7 and a half weeks. 
Premacular hemorrhage (24). – A 19-year-old female patient, receiving oral isotretinoin 
(30 mg kg–1 daily) for 4 months, reported a sudden and painless loss of vision in her left 
eye. The patient underwent additional tests including ophthalmoscopy (eye fundus ex-
amination), fluorescent angiography and optical coherence tomography (OCT), which 
showed premacular hemorrhage. Anamnesis, further examinations (in search of the 
source) and the fact that the hemorrhage occurred during isotretinoin therapy and disap-
peared after cessation of the treatment, with no other predisposing factors, indicate that 
the hemorrhage was an adverse effect of acne treatment. 
Autoimmune thyroiditis and ocular myasthenia gravis (25). – A 19-year-old male patient, 
treated with oral isotretinoin (1 mg kg–1 daily) for 6 months, experienced a sudden episode 
of right eye ptosis, which passed spontaneously after 2 weeks. Following the next week of 
therapy, ptosis of the left eye appeared and also subsided spontaneously. After another 2 
weeks, the patient experienced eye ptosis again, accompanied by double vision. Medical 
history and additional tests indicated thyroiditis with antibodies against thyroid-stimulat-
ing hormone (TSH) receptors and ocular myasthenia gravis, which was confirmed by a good 
response to steroidotherapy with prednisolone (40 mg daily) and pyridostigmine (360 mg 
daily). Simultaneous absence of the factors causing or predisposing to these diseases and the 
fact that isotretinoin may cause other autoimmune diseases (such as Crohn’s disease and 
Guillain-Barre syndrome) indicate their relationship with isotretinoin treatment.
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CONCLUSIONS
Due to the widespread use in clinical practice, the adverse effects of retinoids, includ-
ing ocular effects, should be studied thoroughly. This is particularly important because of 
the fact that many of the adverse effects of these drugs can be predicted (13), which sug-
gests the need for systematic control of patients treated with vitamin A derivatives. The 
frequency of ocular side effects compels practitioners to consider periodic ophthalmologi-
cal controls, particularly in patients with initial ocular symptoms (e.g., dry eye syndrome). 
Such controls would provide the possibility of treating or reducing these adverse effects.
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